Sunday 11 October 2026 Export all SNY data to Excel Powerpack

Sanofi

SNY Healthcare Drug Manufacturers General

Sanofi’s revenue for fiscal 2025 (year ended December 2025) was $52.9 billion, up 10.3% from fiscal 2024. In the quarter to June 2026, revenue grew 17.4%, EPS fell 90.8%, free cash flow fell 45.1% and total debt rose 8.23%, each against the same quarter a year earlier. Dividend growth for three consecutive years.

40.07 0.16 −0.40%
Market cap
$95.9B
P/E
21.0×
Fwd P/E
—
Dividend yield
6.05%
F-score
7/9
Altman Z
2.50
Beneish M
−2.63
Dividend safety
58/100
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

11.29 13.46 13.46 22.34
P/S ratio
2.46 2.24 2.12 1.79
P/FCF ratio
13.00 6.36 6.24 7.02
P/Operating CF
62.81 9.73 9.54 18.91
P/B ratio
1.44 1.46 1.43 1.26
EV/Sales
2.73 2.47 2.39 2.11
EV/EBITDA
13.10 13.29 13.31 11.54
EV/FCF
14.45 7.02 7.03 8.25
Current Ratio
1.06 1.09 1.01 0.99
Net Debt/EBITDA
2.97 10.99 6.08 7.13
Debt/Equity
0.27 0.26 0.25 0.31
Earnings Yield
8.86% 7.43% 7.43% 4.48%
Free Cash Flow Yield
7.69% 15.73% 16.04% 14.24%
Free Cash Flow per Share
0.00 4.98 0.00 2.26
Book value per Share
35.28 33.24 35.55 33.80
Free Cash Flow
— 12,162.55 — 5,398.42
EV/EBIT
13.10 13.29 13.31 11.54
Other line items

Show all line items

Columns are period end dates